CytoMed Therapeutics (GDTC) vs Theriva Biologics (TOVX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Theriva Biologics (TOVX) has outperformed CytoMed Therapeutics (GDTC) over the past year, losing 49.5% versus a loss of 56.5%. CytoMed Therapeutics is the larger company by market cap ($10.5 million vs $10.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GDTC | TOVX |
|---|---|---|
| Share price | $0.8818 | $0.2215 |
| Market cap | $10.52M | $10.17M |
| 1-day change | -6.68% | -2.47% |
| YTD return | -29.22% | +8.14% |
| 1-year return | -56.46% | -49.53% |
| 5-year return | — | -99.79% |
| P/E ratio (TTM) | — | 0.30 |
| EPS (TTM) | $-0.23 | $0.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.68 | $0.86 |
| 52-week low | $0.68 | $0.16 |
| Distance from 52-week high | -76.04% | -74.24% |
| Analyst consensus | none | none |
| Avg. price target upside | +371.76% | +1028.67% |
| Average volume | 78.66K | 525.96K |
| Shares outstanding | 11.93M | 45.89M |
| Employees | 42 | 15 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About CytoMed Therapeutics
GDTC stock →CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.
Health Care · Biotechnology: Pharmaceutical Preparations · 42 employees
About Theriva Biologics
TOVX stock →Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
GDTC vs TOVX FAQ
Which is bigger, CytoMed Therapeutics or Theriva Biologics?
CytoMed Therapeutics (GDTC) is larger, with a market capitalization of $10.52M compared with $10.17M for Theriva Biologics (TOVX).
Which stock has performed better over the past year, GDTC or TOVX?
TOVX returned -49.53% over the past 12 months, compared with -56.46% for GDTC (price return, excluding dividends). Past performance does not predict future results.
Are CytoMed Therapeutics and Theriva Biologics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.